德国Sirion GmbH  
Sirion GmbH develops and distributes gene function analysis tools and services for life sciences R&D in industry and academia. Sirions core competences are adenoviral gene expression systems with emphasis on cellular siRNA expression. This proprietary Q-tech technology allows the direct induction of specific RNA interference in virtually any cell type. In addition, Sirion offers a broad range of customized services for viral gene expression.
SIRION BIOTECH is a young biotech company providing innovative tools and services for functional gene analysis. Based on its outstanding expertise in gene expression and adenoviral technology, SIRION BIOTECH offers a broad range of R&D in biotechnology and pharmacentical industry as well as for academia. SIRION BIOTECH’s key competencies are RNA interference and adenoviral vector technology. Both strengths have been combined to develop SIRION BIOTECH’s unmatched RNA interference technology called Q-tech, allowing transfection-free siRNA-mediated RNA interference.

Founded in 2006 by Lars Behrend and Christian Thirion, both biochemists with sound expertise in virology and cancer biology, SIRION BIOTECH started operation in late 2006, supported by public financing from Bayern Kapital, KfW and HTGF. SIRION BIOTECH is based in Munich/Martinsried (Germany>) one of the European biotechnology hot spots. Having its premises at the IZB (Innovations- und Gruenderzentrum), SIRION BIOTECH has access to an excellent infrastructure and biotechnological competence network allowing to provide excellent and state of the art services to clients.

Currently, the SIRION BIOTECH team consists of 10 scientists and technicians working on the extension of the Q-tech program and developing new gene analysis services. In near future, new tools and services will be offered in the field of micro RNAs and related fields.